top of page
AdobeStock_333408301_edited.jpg

WhartSep is fitting hospital’s constraints, providing “off-the-shelf” cells that can be stored frozen for years prior to being injected to patients.

The product is classified as an ATMP (Advanced-Therapy Medicinal Product) by the EMA (European Medicines Agency).

 

Today, treatments in development, such as mAbs/NCEs are facing similar limitations: 1 drug, 1 mode of action, for multiple combined effects pathology.

 

On the contrary, WhartSep’s biological features show unique advantages, tackling the complexity of severe pneumonia, acting on various aspects of the pathology and adapting to the patient’s needs.

​

WhartSep is in phase Ib entry in severe pneumonia

Capture d’écran 2022-10-24 à 17.46.23.png

WORSENING OF SEPSIS LEADS TO HIGH MORTALITY AND TO HIGH MORBIDITY RATES

Major unmet medical need
 

A costly disease with limited solutions

figures sepsis.png

PARTNERS

R&D

Support

Logo chu.png
Logo UL.png
Logo Grand est region.png
logo IL.png
Logo BPI .png
Logo sayens.png

Labels

i-Lab_600x400_1050515_1050656.jpeg

StemInov SAS
2 avenue de la Forêt de Haye
54520 VANDOEUVRE-LES-NANCY

  • LinkedIn
Logo_FrenchTech_Health20_2023.png

© 2023 by StemInov - All rights reserved

bottom of page